Review anchor
Equilibrative nucleoside transporter 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Equilibrative nucleoside transporter 1
CHEMBL1997
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Equilibrative nucleoside transporter 1 as ChEMBL target CHEMBL1997, mapped to UniProt Q99808. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1997
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q99808
Equilibrative nucleoside transporter 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Equilibrative nucleoside transporter 1 matters
Equilibrative nucleoside transporter 1 is reviewed as Equilibrative nucleoside transporter 1 (UniProt Q99808); Equilibrative nucleoside transporter 1 shows approved-linked disease relevance led by coronary artery disease. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 1450 compounds, and 46 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Equilibrative nucleoside transporter 1
Equilibrative nucleoside transporter 1 Sequence length is 456 aa.
Review this target as Equilibrative nucleoside transporter 1, mapped to UniProt Q99808. Sequence length is 456 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q99808
Protein
Disease context
coronary artery disease
Equilibrative nucleoside transporter 1 shows approved-linked disease relevance led by coronary artery disease. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DIPYRIDAMOLE.
Start review with coronary artery disease because it currently carries approved-linked support. Linked drugs include DIPYRIDAMOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 6 approved drugs, 1450 compounds, and 46 assays for this target. The dominant activity type is IC50. CHEMBL571939 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL571939 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
6 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Equilibrative nucleoside transporter 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q99808, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why coronary artery disease is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1450
Total Compounds
46
Total Assays
6
Approved Drugs
IC50: 233.0, KI: 233.0, EC50: 1.0, KD: 7.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL571939
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL569223
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL126075
|
10.0 | IC50 | Clinical |
|
|
No preferred name
CHEMBL569224
|
9.6 | Kd | — |
|
|
No preferred name
CHEMBL1628717
|
9.6 | Ki | Clinical |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
DIPYRIDAMOLE
CHEMBL932
|
1961 |
Source Header